A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1–associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study
Nicole J. Ullrich(Boston Children's Hospital), Mark W. Kieran(Boston Children's Hospital), Bruce R. Korf(Harvard University), Alan Cantor(Cincinnati Children's Hospital Medical Center), Nathan Robison(University of Southern California), Roger J. Packer(George Washington University), Peter Manley(Boston Children's Hospital), Sanjay P. Prabhu(Boston Children's Hospital), Alyssa Reddy, Coretta Thomas(University of Alabama), Gary Cutter(University of Alabama at Birmingham), David Viskochil(University of Utah), Alexander A. Vinks(Cincinnati Children's Hospital Medical Center), David H. Gutmann(Washington University in St. Louis), Susan Chi, Stewart Goldman(St Nicholas Hospital), John P. Perentesis(Cincinnati Children's Hospital Medical Center), Michael J. Fisher(Children's Hospital of Philadelphia), Jeffrey C. Allen(NYU Langone Health), Tomoyuki Mizuno(Cincinnati Children's Hospital Medical Center)
Cited by 82
Related Papers
Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus
|Cell|1990|1.1k
Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency
|Journal of Clinical Oncology|2016|867
Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation
|Genetics in Medicine|2021|766
Risk stratification of childhood medulloblastoma in the molecular era: the current consensus
|Acta Neuropathologica|2016|650